Solid Biosciences today announced that new preclinical data from its DMD programs will be presented at the 21st Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT).
Solid Biosciences is a life science company focused on solving Duchenne muscular dystrophy. We aim to be the center of excellence across the entire disease spectrum, serving as a catalyst to bring together those with expertise in science, technology, disease management and care. Disease-focused and founded by a family directly impacted by Duchenne muscular dystrophy, our mandate is simple yet comprehensive – attack the roots of the disease and improve daily life for patients.
